← All trials
NCT05257031
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 12, 2022
- Primary completion
- Sep 11, 2022
- Completion date
- Mar 31, 2023
- First posted
- Feb 25, 2022
- Last posted
- Oct 3, 2022
- Enrollment
- 56
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- FreseniusLead sponsor
- Government of RussiaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.